Education and Innovation in Cardiovascular Medicine
News • 20-8-2014

Prof. dr. Freek Verheugt: “Role of aspirin in cancer mortality far from clear”

Prof. dr. F.W.A. Verheugt (Amsterdam) responds to an article in Ann Oncol of this week about the effect of prophylactic aspirin use with regard to cancer and CVD events. Read more

Link between sodium intake and CV disease less straightforward than previously thought

18-8-2014 • Mente et al., NEJM 2014
Three studies published in the NEJM examine the relationships between sodium or potassium intake and blood pressure and CV outcomes and find that current recommendations may not be adequate. Read more
News • 12-8-2014

CVD risk in diabetes type 1 or type 2: more of the same, or very different?

AHA and ADA reviewed current insights into differences in pathophysiology between T1DM and T2DM, and call for more research into the mechanism of CVD risk in T1DM. Read more
News • 12-8-2014

Towards better strategies for heart failure with preserved ejection fraction

International experts discuss possible explanations of previous negative results of phase III trials for HFpEF, and advocate better phenotyping and suggest approaches for future HFpEF trials. Read more
News • 11-8-2014

AHA/ASA advises to discuss risk of cervical arterial dissection before neck manipulation

Although a causal relation has not been shown, patients should be informed about the statistical association between cervical manipulative therapy and cervical dissection. Read more

Patients’ perception of treatment burden greatly affects net benefit of lowering HbA1c

7-8-2014 • Vijan S et al., JAMA Intern Med. 2014
If moderate control of HbA1c level (9%) is achieved, a patient’s view of treatment burden is the most important factor determining the net benefit of glucose-lowering treatment. Read more

Physician continuity improves outcomes of HF patients after treatment and release from ED

6-8-2014 • Sidhu RS et al., JACC Heart Fail. 2014
Follow-up with a familiar physician was associated with a lower risk of death or hospitalisation, as compared with HF patients who see different or no physicians after ED discharge. Read more

Digoxin treatment increases mortality risk in patients with newly diagnosed AF

12-8-2014 • Turakhia MP et al., J Am Coll Cardiol. 2014
Although digoxin is endorsed by cardiology guidelines in AF, in TREAT-AF its use was associated with increased mortality, irrespective of treatment adherence and renal dysfunction. Read more
News • 11-8-2014

Primary prevention of cancer and CVD with aspirin use for over 5 years gives net long-term benefit

Prophylactic aspirin use for at least 5 years at doses between 75 and 325 mg/day seems to have a favourable benefit-harm profile, with regard to cancer and CVD events. Read more

Better stroke outcome for all with alteplase treatment within 4.5 hours

7-8-2014 • Emberson J et al., The Lancet 2014
Alteplase treatment increases the odds of good stroke outcome, with earlier treatment resulting in larger benefits, irrespective of age and severity of stroke. Read more

Treatment targeting LDL particle numbers results in better clinical outcome than LDL-c levels

6-8-2014 • Toth et al., Atherosclerosis. 2014
Increases of LDL-P levels are associated with higher risk of CHD events, after accounting for LDL-c levels and patients in whom LDL-P was measured, received more potent statin therapy. Read more
News • 5-8-2014

European Commission approves apixaban for treatment and prevention of recurrent DVT and PE

The efficacy and safety of apixaban in the treatment of recurrent VTE/VTE-related death had been demonstrated in clinical trials AMPLIFY and AMPLIFY-NXT. Read more